Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.

Tolaney, Sara M.Jiang, ZefeiZhang, QingyuanBarroso-Sousa, RomualdoPark, Yeon HeeRimawi, Mothaffar F.Saura Manich, CristinaSchneeweiss, AndreasToi, MasakazuChae, Yee SooKemal, YaseminChaudhari, MukeshYamashita, ToshinariCasalnuovo, MonicaDanso, Michael A.Liu, JieShetty, JagdishHerbolsheimer, Pia MaaritLoibl, Sibylle2025-08-142025-08-142025Tolaney, S. M., Jiang, Z., Zhang, Q., Barroso-Sousa, R., Park, Y. H., Rimawi, M. F., ... & Loibl, S. (2025). Trastuzumab deruxtecan (T-DXd)+ pertuzumab (P) vs taxane+ trastuzumab+ pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. 10.1200/JCO.2025.43.17_suppl.LBA10080732-183X1527-7755https://hdl.handle.net/20.500.12939/5879...eninfo:eu-repo/semantics/closedAccessOncologyTrastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.Other10.1200/JCO.2025.43.17_suppl.LBA10084317_SUPPLLBA1008LBA1008Q1